Next Article in Journal
Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma
Next Article in Special Issue
ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma
Previous Article in Journal
Next-Generation Molecular Imaging of Thyroid Cancer
Previous Article in Special Issue
Neutrophil-to-Lymphocyte Ratio as a Biomarker Predicting Overall Survival after Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma
 
 
cancers-logo
Article Menu

Article Menu

Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Multicenter Propensity Score-Based Study of Laparoscopic Repeat Liver Resection for Hepatocellular Carcinoma: A Subgroup Analysis of Cases with Tumors Far from Major Vessels

by Arimasa Miyama 1, Zenichi Morise 1,*, Luca Aldrighetti 2, Giulio Belli 3, Francesca Ratti 2, Tan-To Cheung 4, Chung-Mau Lo 4, Shogo Tanaka 5, Shoji Kubo 5, Yukiyasu Okamura 6, Katsuhiko Uesaka 6, Kazuteru Monden 7, Hiroshi Sadamori 7, Kazuki Hashida 8, Kazuyuki Kawamoto 8, Naoto Gotohda 9, KuoHsin Chen 10,11, Akishige Kanazawa 12, Yutaka Takeda 13, Yoshiaki Ohmura 13, Masaki Ueno 14, Toshiro Ogura 15, Kyung-Suk Suh 16, Yutaro Kato 17, Atsushi Sugioka 17, Andrea Belli 18, Hiroyuki Nitta 19, Masafumi Yasunaga 20, Daniel Cherqui 21,22, Nasser Abdul Halim 21, Alexis Laurent 22, Hironori Kaneko 23, Yuichiro Otsuka 23, Ki-Hun Kim 24, Hwui-Dong Cho 24, Charles Chung-Wei Lin 25,26, Yusuke Ome 27, Yasuji Seyama 27, Roberto I. Troisi 28,29, Giammauro Berardi 29, Fernando Rotellar 30, Gregory C. Wilson 31, David A. Geller 31, Olivier Soubrane 32, Tomoaki Yoh 32, Takashi Kaizu 33, Yusuke Kumamoto 33, Ho-Seong Han 34, Ela Ekmekcigil 34, Ibrahim Dagher 35, David Fuks 36, Brice Gayet 36, Joseph F. Buell 37, Ruben Ciria 38, Javier Briceno 38, Nicholas O’Rourke 39, Joel Lewin 39, Bjorn Edwin 40, Masahiro Shinoda 41, Yuta Abe 41, Mohammed Abu Hilal 42,43, Mohammad Alzoubi 43,44, Minoru Tanabe 15 and Go Wakabayashi 45add Show full author list remove Hide full author list
1
Department of Surgery, Okazaki Medical Center, Fujita Health University School of Medicine, Okazaki 444-0827, Japan
2
Hepatobiliary Division in Department of Surgery, San Raffaele Hospital, 20132 Milano, Italy
3
Department of General and HPB Surgery, Loreto Nuovo Hospital, 80121 Naples, Italy
4
Division of HBP and Liver Transplant, University of Hong Kong Queen Mary Hospital, Hong Kong 999077, China
5
Department of Hepato-Biliary-Pancreatic Surgery, Graduate School of Medicine, Osaka City University, Osaka 545-8586, Japan
6
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Shizuoka 411-8777, Japan
7
Departments of Surgery, Fukuyama City Hospital, Fukuyama 721-8511, Japan
8
Department of Surgery, Kurashiki Central Hospital, Kurashiki 710-8602, Japan
9
Division of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan
10
Division of General Surgery, Department of Surgery, Far-Eastern Memorial Hospital, New Taipei City 220, Taiwan
11
Department of Electrical Engineering, Yuan Ze University, Chung-Li 32003, Taiwan
12
Department of Hepato-Biliary-Pancreatic Surgery, Osaka City General Hospital, Osaka 534-0021, Japan
13
Department of Surgery, Kansai Rosai Hospital, Amagasaki 660-8511, Japan
14
Second Department of Surgery, Wakayama Medical University, Wakayama 641-5810, Japan
15
Department of Hepatobiliary and Pancreatic Surgery, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo 113-8519, Japan
16
Department of Hepatobiliary and Pancreatic Surgery, Seoul National University Hospital, Seoul 03080, Korea
17
Department of Gastrointestinal Surgery, School of Medicine, Fujita Health University, Toyoake 470-1192, Japan
18
Department of Abdominal Surgical Oncology, Fondazione G.Pascale-IRCCS, National Cancer Institute of Naples, 80131 Napoli, Italy
19
Department of Surgery, Iwate Medical University, Iwate 028-3695, Japan
20
Department of Surgery, School of Medicine, Kurume University, Kurume 830-0011, Japan
21
Department of Hepato-Biliary Surgery and Transplantation, Hepatobiliary Centre, Paul Brousse Hospital, Villejuif 94800, France
22
Department of Digestive, Hepatobiliary, Pancreatic Surgery and Liver Transplantation, Hôpital Henri Mondor, Assistance Publique-Hôpitaux de Paris, 94010 Créteil, France
23
Division of General and Gastroenterological Surgery, Department of Surgery, Toho University Faculty of Medicine, Tokyo 143-8541, Japan
24
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Ulsan University and Asan Medical Center, Seoul 05505, Korea
25
Department of Surgery and Surgical Oncology, Koo Foundation Sun Yat-Sen Cancer Center, Taipei 11259, Taiwan
26
IRCAD-AITS, Changhua County 505, Taiwan
27
Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo 113-8677, Japan
28
Department of Clinical Medicine and Surgery, University of Naples Federico II, 80138 Napoli, Italy
29
General Hepato-Biliary and Liver Transplantation Surgery, Ghent University Hospital Medical School, 9000 Gent, Belgium
30
HPB and Liver Transplant Unit, Clinica Universitaria de Navarra, 31008 Pamplona, Spain
31
Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15260, USA
32
Department of HPB Surgery and Liver Transplant, Beaujon Hospital, 92110 Clichy, France
33
Department of Surgery, School of Medicine, Kitasato University, Sagamihara 252-0375, Japan
34
Department of Surgery, College of Medicine, Seoul National University, Bundang Hospital, Gyeonggi-do, Seongnam 13620, Korea
35
Department of Minimally Invasive Digestive Surgery, Antoine Béclère Hospital, 92140 Clamart, France
36
Department of Digestive Diseases, Institute Mutualiste Montsouris, University of Paris Descartes, 75014 Paris, France
37
Department of Surgery, Tulane Transplant Abdominal Institute, Tulane University, New Orleans, LA 70118, USA
38
Unit of Hepatobiliary Surgery and Liver Transplantation, University Hospital Reina Sofia, 14004 Córdoba, Spain
39
Department of General Surgery and HPB Surgery, Royal Brisbane Hospital, The University of Queensland, Herston, Brisbane, QLD 4029, Australia
40
Department of Hepatopancreatobiliary Surgery, Oslo University Hospital-Rikshospitalet, 0372 Oslo, Norway
41
Department of Surgery, School of Medicine, Keio University, Tokyo 160-8582, Japan
42
Department of Surgery, Istituto Ospedaliero–Fondazione Poliambulanza, 25124 Brescia, Italy
43
Department of Surgery, University Hospital of Southampton NHS Foundation Trust, Southampton SO16 6YD, UK
44
Department of General Surgery, Jordan University Hospital, The University of Jordan, Amman 11942, Jordan
45
Department of Surgery, Ageo Central General Hospital, Ageo 362-8588, Japan
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(13), 3187; https://doi.org/10.3390/cancers13133187
Submission received: 30 May 2021 / Revised: 17 June 2021 / Accepted: 21 June 2021 / Published: 25 June 2021
(This article belongs to the Special Issue Novel Therapies for Hepatocellular Carcinoma)

Abstract

:

Simple Summary

Less morbidity is considered among the advantages of laparoscopic liver resection for HCC patients. However, our previous international, multi-institutional study of laparoscopic repeat liver resection (LRLR) failed to prove it. We hypothesize that these results may be since the study included complex cases performed during the procedure’s developing stage. To examine it, subgroup analysis based on propensity score were performed, defining the proximity of the tumors to major vessels as the complexity. A propensity score matching earned 115 each patient of LRLR and open repeat liver resection (ORLR) without the proximity to major vessels, and the outcomes were compared. With comparable operation time and long-term outcome, less blood loss and less morbidity were shown in LRLR group than ORLR. Even in its worldwide developing stage, LRLR for HCC patients could be beneficial in blood loss and morbidity for the patients with less complexity in surgery.

Abstract

Less morbidity is considered among the advantages of laparoscopic liver resection (LLR) for HCC patients. However, our previous international, multi-institutional, propensity score-based study of emerging laparoscopic repeat liver resection (LRLR) failed to prove this advantage. We hypothesize that these results may be since the study included complex LRLR cases performed during the procedure’s developing stage. To examine it, subgroup analysis based on propensity score were performed, defining the proximity of the tumors to major vessels as the indicator of complex cases. Among 1582 LRLR cases from 42 international high-volume liver surgery centers, 620 cases without the proximity to major vessels (more than 1 cm far from both first–second branches of Glissonian pedicles and major hepatic veins) were selected for this subgroup analysis. A propensity score matching (PSM) analysis was performed based on their patient characteristics, preoperative liver function, tumor characteristics and surgical procedures. One hundred and fifteen of each patient groups of LRLR and open repeat liver resection (ORLR) were earned, and the outcomes were compared. Backgrounds were well-balanced between LRLR and ORLR groups after matching. With comparable operation time and long-term outcome, less blood loss (283.3±823.0 vs. 603.5±664.9 mL, p = 0.001) and less morbidity (8.7 vs. 18.3 %, p = 0.034) were shown in LRLR group than ORLR. Even in its worldwide developing stage, LRLR for HCC patients could be beneficial in blood loss and morbidity for the patients with less complexity in surgery.

1. Introduction

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy [1,2] with the neoplastic background of chronic liver diseases (CLD) [3]. The CLD background can develop multifocal and metachronous oncogeneses and repeat liver resections (LR) are often applied [4]. The indications for laparoscopic LR (LLR) have been expanded with accumulated experiences and developed instruments [5,6,7,8]. Reports of laparoscopic repeat liver resections (LRLR) are also increasing.
We had conducted a retrospective, international propensity score-based study of repeat LR for HCC to clarify the indications and outcomes of LRLR for HCC [9]. The study, with 1582 repeat LRs for HCC at 42 global high-volume liver surgery centers, showed that LRLR was feasible for selected patients and not inferior to open procedures in both the short- and long-term outcomes. The study also showed the differences in experiences and indications of LRLR between the centers, which means this procedure is still in its developing stage worldwide.
Less morbidity has been considered among the advantages of LLR for HCC with CLD patients. However, our previous study of LRLR failed to prove this advantage. We hypothesize that these results may be since the study included complex LRLR cases performed during its international developing stage. To examine the hypothesis, subgroup analyses of cases with less complexity based on propensity score were performed, defining the proximity of the tumors to major vessels, which increases the operative technical difficulty in both open LR and LLR [10,11], as the indicator of complex cases.

2. Methods

2.1. Participating Centers and Total Patients

The study involved 42 high-volume liver surgery centers from around the world that provided data of patients who underwent repeat LR (RLR) for HCC between January 2007 and December 2017. Institutional Review Board (IRB) approval was obtained from the coordinating center, with a data transfer agreement and IRB approval having been provided by all centers.
The centers registered 1582 patients, 934 and 648 treated by open and laparoscopic RLR, respectively, including those who had undergone RLR previously. Each case was discussed under a multidisciplinary setting in each center, and each patient provided informed consent for the procedure.
This study confirmed to the ethical guidelines of Declaration of Helsinki and was retrospective in nature. Approval from the ethics committee of each institution was obtained (HM20-094 for primary investigator’s institution, FHU).

2.2. Data Collection, Division of Patients into Groups, and Comparative Analysis

The following data were obtained: patient characteristics (age, sex, body mass index (BMI), and preoperative performance status); indicators of preoperative liver function (presence of liver fibrosis, background liver inflammation, plasma total bilirubin level (mg/dL), plasma albumin level (g/dL), platelet count (/μL), and prothrombin time); preoperative ascites, encephalopathy, and varices (each expressed as the related Child-Pugh score); tumor characteristics (number of tumors, size (mm), and location (anterolateral vs. posterosuperior segments), proximity to major vessels (Hilar plate-second branches of Glissonian pedicle (≤1 cm or >1 cm) and first–second branches of Major hepatic veins (≤1 cm or >1 cm)); and surgical procedures (open or laparoscopic LR, type of resection (partial resection-segmentectomy, sectionectomy, resection of two or more sections), and the previous LR procedure (open vs. laparoscopic)).
Among 1582 RLR cases, 614 cases without the proximity to major vessels (more than 1 cm far from both first–second branches of Glissonian pedicles and major hepatic veins) were selected for this subgroup analysis. These patients were divided into LRLR (n = 328) and open RLR (ORLR, n = 286) patients.

2.2.1. Propensity Score Matching (PSM) Analysis

For all 614 cases, propensity scores (PS) were calculated based on their patient characteristics, preoperative liver function, tumor characteristics and surgical procedures, which were listed previously, and matching was performed by the scores. Operative and short-term postoperative outcomes (intraoperative blood loss volume (mL), need for blood transfusion, operation time (minutes), 90-day morbidity (≥Clavien–Dindo Grade (CD) II), 90-day morbidity (≥CD IIIa), 90-day mortality, postoperative hospital stay (days), and overall survival after RLR) were assessed, comparing between LRLR and ORLR groups before and after matching.

2.2.2. Inverse Probability Treatment Weighted Analysis

In addition to PSM, 90-day morbidity (≥CD II), 90-day morbidity (≥CD IIIa), and overall survival after RLR were also compared between original (before matching) LRLR and ORLR patients using inverse probability treatment weight (IPTW). For all 614 patients, probability of receiving LRLR was calculated with logistic regression analysis using the same covariates as used in PSM analysis. The IPTW for each patient was defined as 1/probability for LRLR or 1/(1-probability) for ORLR patients. Weighting the outcome from each patient out of total 614 patients using IPTW, 90-day morbidity (≥Clavien–Dindo Grade (CD) II), 90-day morbidity (≥CD IIIa), and overall survival after RLR were compared between the groups.

2.3. Statistical Analyses

Data are expressed as median or mean ± standard deviation or as the number of patients. Between-group differences in categorical variables were analyzed by Pearson’s chi-squared test or Fisher’s exact test with Yates correction, as appropriate. Between-group differences in continuous parametric variables were analyzed by unpaired Student’s t-test or ANOVA, and between-group differences in continuous non-parametric variables were analyzed by the Mann–Whitney or the Kruskal–Wallis test. The correlation between the parameters were analyzed using Pearson’s correlation coefficient. Statistical analyses were performed with SPSS Statistics 25 (IBM Corp., Armonk, NY, USA), and p < 0.05 was considered statistically significant.
Patients were assigned propensity scores based on the factors listed above except outcomes.

3. Results

The LRLR group generally had better outcomes than the ORLR with the differences of background factors before matching (Table 1 and Table 2).
One hundred and fifteen of each PS-matched patients’ groups of LRLR and ORLR were earned. After PSM, backgrounds were well-balanced between the LRLR and the ORLR groups, except for background liver condition (Table 3).
The LRLR group matching had more patients with liver fibrosis or cirrhosis after. Less blood loss (283.3 ± 823.0 vs. 603.5 ± 664.9 mL, p = 0.001) and less morbidity (≥CD II, 8.7 vs. 18.3 %, p = 0.034; ≥CDIII, 4.3 vs. 12.2%, p = 0.031) were shown in the LRLR group than in the ORLR group. The operation times were comparable (260.6 ± 158.3 vs. 270.0 ± 129.6 mL, p = 0.622). The length of post-operative hospital stay was shorter, but not significant, in the LRLR group (10.2 ± 11.3 vs. 13.2 ± 12.1 mL, p = 0.058). As show in Table 4, the median overall survival for ORLR and LRLR were 7.51 and 7.14 years, respectively, and the difference of survival curves were not significant (p = 0.661, Figure 1).
The IPTW analyses for 614 original patients without matching showed less morbidity in LRLR patients (≥CD II, odd ratio = 0.540 (0.339–0.859), p = 0.009; ≥CDIII, 0.450 (0.255–0.797), p = 0.006) with comparable overall survival time (hazard ratio = 0.986 (0.721–1.349), p = 0.93).

4. Discussion

The present study showed a smaller amount of blood loss, less morbidity, a comparable operation time with comparable overall survival in LRLR patients with HCC more than 1 cm far from major vessels as compared to the ORLR counterpart. Although our previous study of 1582 RLRs for HCC [9] showed that LRLR was not inferior to ORLR and feasible for selected patients, the operation time was longer, and morbidity was similar in LRLR compared to the ORLR patients. The previous study also revealed notable differences in the indication of LRLR, even though all participants attended high-volume centers. The LRLR numbers and percentages among RLR had large differences between centers and, furthermore, the numbers and percentages were not correlated. This fact means that this procedure is applied depending on each centers’ experience and indication and the procedure is still in its developing stage worldwide, though it had been already a stable procedure in several institutions. The results of present study can be translated that LRLR for HCC patients could have merits in blood loss and morbidity without elongation of operation time for the patients with less complex surgery, even in its current developing stage. The length of hospital stay was also shorter (not significant) in the LRLR group of the present study, unlike the results from the previous study for the patients, including those with HCC near to major vessels.
The smaller amount of blood loss, lesser morbidity, and shorter length of hospital stays in LLR patients were shown in the first reported propensity score-based analysis of primary LLR and OLR for HCC [12]. However, a similar study for colorectal liver metastases failed to show decreased morbidity [13]. This has been thought to be due to the different liver backgrounds between these two most common diseases for LR. The minimal invasiveness of LLR can be more advantageous for CLD background in HCC patients [14]. Reports of LRLR are increasing [9,15,16,17,18,19,20], and investigators have noted its merits that LLR, with its magnified view, facilitates the meticulous dissection of adhesions strained by the pneumoperitoneum [16] and, furthermore, adhesiolysis can be avoided when the adhesion does not affect the operative procedure [15,18]. Other than our previous report, there are two propensity score matching analyses [21,22] and a meta-analysis of LRLR [23]. They reported smaller amount of blood loss and shorter hospital stay, but not less morbidity. However, they were the studies of HCC patients with CLD backgrounds. In our previous study for LRLR in HCC patients, less morbidity, which has been considered among the advantages of LLR for HCC with CLD patients [14], also failed to be proven. In order to examine the hypothesis that this may be due to the inclusion of complex cases performed during the procedure’s developing stage, subgroup analyses were performed in the present study, defining the proximity of the tumors to major vessels as the indicator of complex cases.
LRLR is generally applied to patients with poor liver function, under the consideration for the advantage of LLR with the preservation of the collateral vessels around liver and less damage to the adjacent structures. In the present study, the difference of background livers between LRLR and ORLR still existed after matching. However, it should have worked in favor of the ORLR group. Even under this condition, the LRLR group showed less morbidity after matching in addition to a smaller amount of blood loss. For the previous surgery after matching, there was no significant difference except for the tendency of LRLR patients having previous laparoscopic LR. Though it might reduce the amount of blood loss, the difference in blood loss was large between the LRLR and the ORLR groups, and our previous study [9] for total group patients has already shown reduced blood loss for LRLR patients. The tumor location and the extent of the resection in RLR were well-matched. However, we had the limitation of not having enough data of those in previous surgery. Shorter length of hospital stay should be one of the advantages of laparoscopic surgery. However, there was no significant difference in those between the LRLR and ORLR groups after matching in the present study, even with the tendency of shorter hospital stay in the LRLR group. There were large differences in hospital stay between centers, areas, and countries, possibly due to insurance systems and hospitalization practices. This might be the reason why the present study failed to show the significant difference in length of hospital stay.
In this subgroup analysis, advantages of LRLR over open, smaller amount of blood loss and less morbidity, were shown for the patients of less complex surgery without elongation of operation time nor deterioration of long-term outcome, though the procedure is still in its developing stage. Several institutions with advanced technique and many experiences in LRLR reported their promising results [15,16,17,18,19]. Although the procedure had been standardized with merits in those institutions, it is still the question to be investigated whether the procedure could become a common surgical procedure in many hospitals in the near future. The surprising speed of LLR development during quarter century from its start raises the expectations.

5. Conclusions

In this subgroup analysis, advantages of LRLR over open, smaller amount of blood loss and less morbidity, were shown for the patients of less complex surgery without elongation of operation time nor deterioration of long-term outcome, though the procedure is still in its developing stage.

Author Contributions

Conceptualization, Z.M., L.A. and G.B.; methodology, Z.M.; software, A.M.; validation, Z.M.; formal analysis, A.M.; investigation, all authors; resources, all authors; data curation, all authors; writing—original draft preparation, A.M.; writing—review and editing, Z.M.; supervision, D.C., M.T. and G.W.; project administration, Z.M. All authors have read and agreed to the published version of the manuscript.

Funding

This study has no related funding.

Institutional Review Board Statement

This study conformed to the ethical guidelines of Declaration of Helsinki and was retrospective in nature. Approval from the ethics committee of each institution was obtained (HM20-094 approved at 17 August 2020 for primary investigator’s institution, FHU).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are available on request from the corresponding author.

Conflicts of Interest

All authors declare no conflict of interest nor sources of funding related to this study.

References

  1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef] [PubMed]
  2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin. 2018, 68, 7–30. [Google Scholar] [CrossRef]
  3. Morise, Z.; Kawabe, N.; Tomishige, H.; Nagata, H.; Kawase, J.; Arakawa, S.; Yoshida, R.; Isetani, M. Recent advances in the surgical treatment of hepatocellular carcinoma. World J. Gastroenterol. 2014, 20, 14381–14392. [Google Scholar] [CrossRef]
  4. Itamoto, T.; Nakahara, H.; Amano, H.; Kohashi, T.; Ohdan, H.; Tashiro, H.; Asahara, T. Repeat hepatectomy for recurrent hepatocellular carcinoma. Surgery 2007, 141, 589–597. [Google Scholar] [CrossRef]
  5. Nguyen, K.T.; Gamblin, T.C.; Geller, D.A. World review of laparoscopic liver resection-2804 patients. Ann. Surg. 2009, 250, 831–841. [Google Scholar] [CrossRef]
  6. Buell, J.F.; Thomas, M.T.; Rudich, S.; Marvin, M.; Nagubandi, R.; Ravindra, K.V.; McMasters, K.M. Experience with more than 500 minimally inva-sive hepatic procedures. Ann. Surg. 2008, 248, 475–486. [Google Scholar] [CrossRef]
  7. Wakabayashi, G.; Cherqui, D.; Geller, D.A.; Buell, J.F.; Kaneko, H.; Han, H.S.; Asbun, H.; O’rourke, N.; Tanabe, M.; Koffron, A.J.; et al. Recommendations for laparoscopic liver resection: A report from the second international consensus conference held in Morioka. Ann. Surg. 2015, 261, 619–629. [Google Scholar] [CrossRef] [PubMed]
  8. Morise, Z.; Wakabayashi, G. First quarter century of laparoscopic liver resection. World J. Gastroenterol. 2017, 23, 3581–3588. [Google Scholar] [CrossRef] [PubMed]
  9. Morise, Z.; Aldrighetti, L.; Belli, G.; Ratti, F.; Belli, A.; Cherqui, D.; Tanabe, M.; Wakabayashi, G.; Cheung, T.T.; Lo, C.M.; et al. Laparoscopic repeat liver resection for hepatocellular carcinoma: A multicentre propensity score-based study. BJS 2020, 107, 889–895. [Google Scholar] [CrossRef] [PubMed]
  10. Ban, D.; Tanabe, M.; Ito, H.; Otsuka, Y.; Nitta, H.; Abe, Y.; Hasegawa, Y.; Katagiri, T.; Takagi, C.; Itano, O.; et al. A novel difficulty scoring system for laparoscopic liver resection. J. Hepato-Biliary-Pancreat. Sci. 2014, 21, 745–753. [Google Scholar] [CrossRef]
  11. Xu, H.-W.; Li, H.-Y.; Liu, F.; Wei, Y.-G.; Li, B. Laparoscopic Versus Open Liver Resection for Lesions Adjacent to Major Vessels: A Propensity Score Matched Analysis. J. Laparoendosc. Adv. Surg. Technol. 2017, 27, 1002–1008. [Google Scholar] [CrossRef]
  12. Takahara, T.; Wakabayashi, G.; Beppu, T.; Aihara, A.; Hasegawa, K.; Gotohda, N.; Hatano, E.; Tanahashi, Y.; Mizuguchi, T.; Kamiyama, T.; et al. Long-term and perioperative outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with propensity score matching: A multi-institutional Japanese study. J. Hepato-Biliary-Pancreat. Sci. 2015, 22, 721–727. [Google Scholar] [CrossRef] [PubMed]
  13. Beppu, T.; Wakabayashi, G.; Hasegawa, K.; Go, W.; Mizuguchi, T.; Takahashi, Y.; Hirokawa, F.; Taniai, N.; Watanabe, M.; Katou, M.; et al. Long-term and perioperative outcomes of laparoscopic versus open liver resection for colorectal liver metastases with propensity score matching: A multi-institutional Japanese study. J. Hepato-Biliary-Pancreat. Sci. 2015, 22, 711–720. [Google Scholar] [CrossRef] [PubMed]
  14. Morise, Z.; Ciria, R.; Cherqui, D.; Chen, K.H.; Belli, G.; Wakabayashi, G. Can we expand the indications for laparoscopic liver resec-tion? A systematic review and meta-analysis of laparoscopic liver resection for patients with hepatocellular carcinoma and chronic liver disease. J. Hepatobiliary Pancreat. Sci. 2015, 22, 342–352. [Google Scholar] [CrossRef]
  15. Morise, Z. Status and perspective of laparoscopic repeat liver resection. World J. Hepatol. 2018, 10, 479–484. [Google Scholar] [CrossRef] [PubMed]
  16. Belli, G.; Cioffi, L.; Fantini, C.; D’Agostino, A.; Russo, G.; Limongelli, P.; Belli, A. Laparoscopic redo surgery for recurrent hepatocellular carcinoma in cirrhotic patients: Feasibility, safety, and results. Surg. Endosc. 2009, 23, 1807–1811. [Google Scholar] [CrossRef]
  17. Shafaee, Z.; Kazaryan, A.M.; Marvin, M.R.; Cannon, R.; Buell, J.F.; Edwin, B.; Gayet, B. Is Laparoscopic Repeat Hepatectomy Feasible? A Tri-institutional Analysis. J. Am. Coll. Surg. 2011, 212, 171–179. [Google Scholar] [CrossRef]
  18. Hu, M.; Zhao, G.; Xu, D.; Liu, R. Laparoscopic Repeat Resection of Recurrent Hepatocellular Carcinoma. World J. Surg. 2010, 35, 648–655. [Google Scholar] [CrossRef]
  19. Kanazawa, A.; Tsukamoto, T.; Shimizu, S.; Kodai, S.; Yamamoto, S.; Yamazoe, S.; Nakajima, T. Laparoscopic liver resection for treating re-current hepatocellular carcinoma. J. Hepatobiliary Pancreat. Sci. 2013, 20, 512–517. [Google Scholar] [CrossRef]
  20. Wakabayashi, T.; Felli, E.; Memeo, R.; Mascagni, P.; Abe, Y.; Kitagawa, Y.; Pessaux, P. Short-term outcomes of laparoscopic repeat liver resection after open liver resection: A systematic review. Surg. Endosc. 2019, 33, 2083–2092. [Google Scholar] [CrossRef] [PubMed]
  21. Van der Poel, M.J.; Barkhatov, L.; Fuks, D.; Berardi, G.; Cipriani, F.; Aljaiuossi, A.; Lainas, P.; Dagher, I.; D’Hondt, M.; Rotellar, F.; et al. Multicentre propensity score-matched study of laparoscopic versus open repeat liver resection for colorectal liver metastases. Br. J. Surg. 2019, 106, 783–789. [Google Scholar] [CrossRef] [PubMed]
  22. Hallet, J.; Sa Cunha, A.; Cherqui, D.; Ayet, B.; Goéré, D.; Bachellier, P.; Pessaux, P. French Colorectal Liver Metastases Working Group, As-sociation Française de Chirurgie. Laparoscopic compared to open repeat hepatectomy for colorectal liver metastases: A mul-ti-institutional propensity-matched analysis of short- and long-term outcomes. World J. Surg. 2017, 41, 3189–3198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Peng, L.; Zhou, Z.; Xiao, W.; Hu, X.; Cao, J.; Mao, S. Systematic review and meta-analysis of laparoscopic versus open repeat hepa-tectomy for recurrent liver cancer. Surg. Oncol. 2019, 28, 19–30. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Overall survival curves after propensity score matching. Median overall survivals for open repeat liver resection (ORLR, thin line) and laparoscopic repeat liver resection (LRLR, thick line) were 7.51 and 7.14 years, respectively, and the difference of survival curves were not significant (p = 0.661).
Figure 1. Overall survival curves after propensity score matching. Median overall survivals for open repeat liver resection (ORLR, thin line) and laparoscopic repeat liver resection (LRLR, thick line) were 7.51 and 7.14 years, respectively, and the difference of survival curves were not significant (p = 0.661).
Cancers 13 03187 g001
Table 1. Patient and tumor backgrounds before propensity score matching.
Table 1. Patient and tumor backgrounds before propensity score matching.
BackgroundsORLR (n = 287)LRLR (n = 328)p Value
Age (years)67.3 ± 9.867.7 ± 10.80.665
Sex ratio (Male:Female)222:61252:740.734
BMI (kg/m2)23.1 ± 3.623.9 ± 3.70.009
Performance status
02492560.022
13671
213
312
Number of tumors1.47 ± 1.131.22 ± 0.60<0.001
Tumor size (mm)17.5 ± 11.516.3 ± 12.00.222
Tumor location
Anterolateral1782470.001
Posterosuperior10985
Background liver pathology
NL3040<0.001
CH5221
LF88103
LC100166
Total Billirubin (mg/dL)0.79 ± 0.440.82 ± 0.530.404
Prothronbin time (C-P score)
1:>70% (<1.7)2693130.983
2: 40–70% (1.7–2.3)78
3:<40 (>2.3)33
Creatinine(mg/dL)0.88 ± 0.680.90 ± 0.600.606
Albumin(g/L)4.05 ± 0.444.01 ± 0.470.255
Platelet count (×103/) μL165.5 ± 180.9216.1 ± 350.70.028
ICG R1514.6 ± 8.415.1 ± 10.10.537
Ascites (C-P score)
12823140.011
2519
300
Encephalopathy (C-P score)
12863310.652
212
300
Varices (C-P score)
12562880.033
21129
3612
Extent of resection
Partial resection/segmentectomy2523090.008
Sectionectomy2020
≥2 sections143
Previous surgery
Open Liver resection241120<0.001
Laparoscopic liver resection23149
ORLR, open repeat liver resection; LRLR, laparoscopic repeat liver resection; BMI, body mass index; NL, normal liver; CH, chronic hepatitis; LF, liver fibrosis; LC, liver cirrhosis; C-P score, Child-Pugh score; ICGR15, Indocyanine green retention rate at 15 min; Bold and plain letters [in the left end column] make the separation between heading and selective items.
Table 2. Short-term outcomes before propensity score matching.
Table 2. Short-term outcomes before propensity score matching.
OutcomesORLR (n = 286)LRLR (n = 328)p Value
Intraoperative Blood Loss (mL)629.0 ± 882.3246.6 ± 570.5<0.001
Blood transfusion
No2433060.008
Yes4025
Operation time (min)261.1 ± 159.6235.2 ± 144.70.036
90-day morbidity ≥ CD II
No2432960.059
Yes4232
90-day morbidity ≥ CD IIIa
No2603160.008
Yes2512
90-day mortality
No2823260.253
Yes31
Postoperative hospital stay (days)13.5 ± 11.69.6 ± 8.7<0.001
ORLR, open repeat liver resection; LRLR, laparoscopic repeat liver resection; Bold and plain letters [in the left end column] make the separation between heading and selective items.
Table 3. Patient and tumor backgrounds after propensity score matching.
Table 3. Patient and tumor backgrounds after propensity score matching.
BackgroundsORLR (n = 115)LRLR (n = 115)p Value
Age (years old)67.5 ± 9.568.2 ± 10.30.565
Sex ratio (Male: Female)94:2191:240.618
BMI (kg/m2)23.6 ± 3.523.6 ± 3.60.933
Performance status
0103990.367
11116
210
300
Number of tumors1.45 ± 1.051.28 ± 0.820.164
Tumor size (mm)14.5 ± 9.014.9 ± 12.70.792
Tumor location
Anterolateral72830.122
Posterosuperior4332
Liver fibrosis
1 NL1116<0.001
2 CH284
3 LF3751
4 LC3944
Total Billirubin (mg/dL)0.76 ± 0.360.82 ± 0.370.258
Prothronbin time (C-P score)
1:>70% (<1.7)1091090.842
2: 40–70% (1.7–2.3)43
3:<40 (>2.3)23
Creatinine(mg/dL)0.85 ± 0.620.90 ± 0.820.667
Albumin(g/L)4.09 ± 0.404.04 ± 0.460.382
Platelet count (×103/) μL145.0 ± 77.0150.9 ± 157.10.715
ICG R1515.6 ± 9.214.5 ± 10.30.378
Ascites (C-P score)
11151130.155
202
300
Encephalopathy (C-P score)
1115115-
200
300
Varices (C-P score)
11091091.000
255
311
Extent of resection
Partial resection/segmentectomy1031080.332
Sectionectomy86
≥2 sections41
Previous surgery
Open Liver resection101900.053
Laparoscopic liver resection1425
ORLR, open repeat liver resection; LRLR, laparoscopic repeat liver resection; BMI, body mass index; NL, normal liver; CH, chronic hepatitis; LF, liver fibrosis; LC, liver cirrhosis; C-P score, Child-Pugh score; ICGR15, Indocyanine green retention rate at 15 min; Bold and plain letters [in the left end column] make the separation between heading and selective items.
Table 4. Short-term outcomes after propensity score matching.
Table 4. Short-term outcomes after propensity score matching.
OutcomesORLR (n = 115)LRLR (n = 115)p Value
Intraoperative Blood Loss (mL)603.5 ± 664.9283.3 ± 823.00.001
Blood transfusion
No991030.420
Yes1612
Operation time (min)270.0 ± 129.6260.6 ± 158.30.623
90-day morbidity ≥ CD II
No941050.034
Yes2110
90-day morbidity ≥ CD IIIa
No1011100.031
Yes145
90-day mortality
No115115-
Yes00
Postoperative hospital stay (days)13.2 ± 12.110.2 ± 11.30.058
ORLR, open repeat liver resection; LRLR, laparoscopic repeat liver resection; Bold and plain letters [in the left end column] make the separation between heading and selective items.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Miyama, A.; Morise, Z.; Aldrighetti, L.; Belli, G.; Ratti, F.; Cheung, T.-T.; Lo, C.-M.; Tanaka, S.; Kubo, S.; Okamura, Y.; et al. Multicenter Propensity Score-Based Study of Laparoscopic Repeat Liver Resection for Hepatocellular Carcinoma: A Subgroup Analysis of Cases with Tumors Far from Major Vessels. Cancers 2021, 13, 3187. https://doi.org/10.3390/cancers13133187

AMA Style

Miyama A, Morise Z, Aldrighetti L, Belli G, Ratti F, Cheung T-T, Lo C-M, Tanaka S, Kubo S, Okamura Y, et al. Multicenter Propensity Score-Based Study of Laparoscopic Repeat Liver Resection for Hepatocellular Carcinoma: A Subgroup Analysis of Cases with Tumors Far from Major Vessels. Cancers. 2021; 13(13):3187. https://doi.org/10.3390/cancers13133187

Chicago/Turabian Style

Miyama, Arimasa, Zenichi Morise, Luca Aldrighetti, Giulio Belli, Francesca Ratti, Tan-To Cheung, Chung-Mau Lo, Shogo Tanaka, Shoji Kubo, Yukiyasu Okamura, and et al. 2021. "Multicenter Propensity Score-Based Study of Laparoscopic Repeat Liver Resection for Hepatocellular Carcinoma: A Subgroup Analysis of Cases with Tumors Far from Major Vessels" Cancers 13, no. 13: 3187. https://doi.org/10.3390/cancers13133187

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop